Prenylamine
Prenylamine[edit]
Prenylamine is a pharmaceutical drug that was primarily used as a calcium channel blocker and antianginal agent. It was developed in the mid-20th century and was used to treat angina pectoris, a condition characterized by chest pain due to reduced blood flow to the heart.
Mechanism of Action[edit]
Prenylamine functions by inhibiting the influx of calcium ions through calcium channels in the cardiac muscle and smooth muscle of the coronary arteries. This action leads to a decrease in myocardial oxygen demand and an increase in coronary blood flow, thereby alleviating the symptoms of angina.
Pharmacokinetics[edit]
Prenylamine is administered orally and is absorbed through the gastrointestinal tract. It undergoes extensive first-pass metabolism in the liver, which affects its bioavailability. The drug is metabolized into several active and inactive metabolites, which are excreted primarily through the urinary system.
Clinical Use[edit]
Prenylamine was used in the management of chronic stable angina. It was considered effective in reducing the frequency and severity of anginal attacks. However, due to the development of newer and safer antianginal medications, the use of prenylamine has declined.
Side Effects[edit]
Common side effects of prenylamine included dizziness, nausea, and fatigue. More serious adverse effects involved cardiac arrhythmias and hypotension. Due to these potential risks, its use was carefully monitored.
Withdrawal from Market[edit]
Prenylamine was eventually withdrawn from the market in many countries due to concerns over its safety profile, particularly the risk of inducing torsades de pointes, a type of life-threatening arrhythmia.
